A PHASE 3, PLACEBO-CONTROLLED, DOUBLE-BLINDED, RANDOMIZED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER
A PHASE 3, PLACEBO-CONTROLLED, DOUBLE-BLINDED, RANDOMIZED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER
The purpose of the study is to learn about how effective, safe, and tolerable the Clostridioides difficile (C. difficile) vaccine is in decreasing the number of C. difficile infections (pCDI) in adults 65 years of age or older.
The participants will receive either the C. difficile vaccine or placebo (saline). A placebo does not contain any active ingredients. The vaccines will be given as a shot into the upper arm muscle.
This study looks at the number of diarrhea (loose stools) events related to a C. difficile infection, so the length of the study can change. If these events happen quickly, the study may finish sooner; if they happen slowly, it could take longer. Sometimes, the study might stop early if the vaccine clearly does not work. Participants will stay in the study until enough events have occurred to answer the main question. On average, each person is expected to take part for up to about three and a half years.
During this time, participants will have 3 planned clinic visits and 3 planned phone visits. After these visits, more scheduled clinic visits will happen every year until the end of study.
Besides the scheduled study visits, if at any time during the study a participant has 3 or more loose stools in 24 hours, they will be asked to save the next one (the fourth or later) and contact the study site. The study site will check to see if it could be a C. difficile infection. This check may happen at the clinic or through a phone or video call.
Who Can Join the Study (Inclusion Criteria):
• People with recent or future planned contact with healthcare systems, recent antibiotic exposure, or a diagnosis of certain chronic medical conditions.
Who Cannot Join the Study (Exclusion Criteria):
ClinicalTrials.gov_Inquiries@pfizer.com1-800-718-1021
San Mateo, California 94403, United States
Toluca Lake, California 91602, United States
Washington D.C., District of Columbia 20037, United States
Jacksonville, Florida 32256, United States
Kenner, Louisiana 70065, United States
West Roxbury, Massachusetts 02132, United States
Hackensack, New Jersey 07601, United States
Neptune City, New Jersey 07753, United States
Neptune City, New Jersey 07753, United States
Sleepy Hollow, New York 10591, United States
High Point, North Carolina 27262, United States
Cleveland, Ohio 44106, United States
Nashville, Tennessee 37212, United States
Houston, Texas 77030, United States
Tomball, Texas 77375, United States
Salt Lake City, Utah 84121, United States
Seattle, Washington 98101, United States
Seattle, Washington 98104, United States
Iizuka-shi, Fukuoka 820-8505, Japan
Kitakyushu-shi, Fukuoka 806-8501, Japan
Onga-gun, Fukuoka 807-0051, Japan
Chuo-ku, Tokyo 103-0027, Japan
Glasgow, Glasgow CITY ML4 3NJ, United Kingdom
Wrexham, Wrexham [wrecsam Gb-wrc] LL13 7YP, United Kingdom